Show simple item record

dc.contributor.authorİçli, Abdullah
dc.contributor.authorCüre, Erkan
dc.contributor.authorCüre, Medine Cumhur
dc.contributor.authorUslu, Ali Uğur
dc.contributor.authorBalta, Şevket
dc.contributor.authorMikhailidis, Dimitri P.
dc.contributor.authorÖztürk, Cengiz
dc.contributor.authorArslan, Şevket
dc.contributor.authorSakız, Davut
dc.contributor.authorŞahin, Muhammed
dc.contributor.authorKüçük, Adem
dc.date.accessioned2020-12-19T19:50:22Z
dc.date.available2020-12-19T19:50:22Z
dc.date.issued2016
dc.identifier.citationIcli, A., Cure, E., Cure, M. C., Uslu, A. U., Balta, S., Mikhailidis, D. P., Ozturk, C., Arslan, S., Sakız, D., Sahin, M., & Kucuk, A. (2016). Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology, 67(8), 749–755. https://doi.org/10.1177/0003319715616240en_US
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.urihttps://doi.org/10.1177/0003319715616240
dc.identifier.urihttps://hdl.handle.net/11436/2421
dc.descriptionCure, Medine Cumhur/0000-0001-9253-6459; Mikhailidis, Dimitri/0000-0002-9566-2263; cure, erkan/0000-0001-7807-135X; Balta, Sevket/0000-0002-6657-7334en_US
dc.descriptionWOS: 000382857900007en_US
dc.descriptionPubMed: 26614790en_US
dc.description.abstractSystemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. A major cause of morbidity and mortality in SLE is accelerated atherosclerosis. Endothelial-specific molecule 1 (endocan) is a potential predictor of vascular events and is expressed in response to inflammatory cytokines in endothelial cells. We investigated the relationship between endocan and carotid intima-media thickness (cIMT) as a marker of early atherosclerosis. We included 44 women with SLE and 44 healthy women as controls. Disease severity of SLE was evaluated using the SLE Disease Activity Index. Endocan, C-reactive protein, erythrocyte sedimentation rate (ESR), and lipid panel were measured. the cIMT was 0.70 (range: 0.45-1.20) mm in patients with SLE and 0.40 (0.25-0.60) mm in controls (P < .001). Endocan value was 1.6 +/- 0.9 ng/mL in controls and 2.2 +/- 1.0 ng/mL in patients with SLE (P = .014). Endocan levels were positively correlated with cIMT (r = .469, P < .001), body mass index (r = .373, P = .013), and ESR (r = .393, P = .008). Endocan level may be associated with subclinical atherosclerosis in SLE. Consequently, endocan levels may be a promising clinical tool for patients with SLE as a guide for preventive strategy.en_US
dc.description.sponsorshipMSD; AstraZenecaAstraZeneca; Libytecen_US
dc.description.sponsorshipThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: DPM has given talks and attended conferences sponsored by MSD, AstraZeneca and Libytec.en_US
dc.language.isoengen_US
dc.publisherSage Publications Incen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndocanen_US
dc.subjectSystemic lupus erythematosusen_US
dc.subjectAtherosclerosisen_US
dc.subjectInflammationen_US
dc.titleEndocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosusen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorCüre, Erkan
dc.contributor.institutionauthorCüre, Medine Cumhur
dc.identifier.doi10.1177/0003319715616240
dc.identifier.volume67en_US
dc.identifier.issue8en_US
dc.identifier.startpage749en_US
dc.identifier.endpage755en_US
dc.relation.journalAngiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record